Rev Esp Quimioter 2021;34(5):459-467

Influence of CMO pharmaceutical care model-based intervention on readmission rate in high risk HIV patients: the INFARDAR study

MARIA ISABEL GUZMÁN RAMOS, MERCEDES MANZANO GARCIA, Mª DE LAS AGUAS ROBUSTILLO-CORTÉS, ANTONIO GUTIÉRREZ PIZARRAYA, RAMÓN MORILLO-VERDUGO

Published: 7 July 2021

http://www.doi.org/10.37201/req/025.2021

Background. Many studies have indicated that hospitalization and readmissions occur frequently, especially among people living with HIV. The aim of the study was to determine the effectiveness of a programmed and structured pharmaceutical intervention, based on “CMO PC model” to reduce the readmission rate in high-risk HIV patients.
Material and methods. This was a single-center, prospective study based on a structured health intervention conducted between March-2017 and March-2018 with 12 months of follow-up at outpatient pharmacy services. At discharge, HIV patients included were classified according to the risk of readmission as low or high risk patients, being the latter proposed to participate. The selected patients were randomly assigned to a control group (usual care) or intervention group (including stratification-motivational interview and new technologies: CMO pharmaceutical care). The primary endpoint was readmission rate at one year of follow-up in each group.
Results. A total of 39 patients were included. As regards the main variable, in the intervention group, 21,4% (n=3) of patients were readmitted in the first year after discharge vs. 66,7% (n=6) in the control group (p=0,042).
Conclusions. Tailored pharmaceutical care based on risk stratification, motivational interviewing, and new technologies has a positive influence to reduce the percentage of readmission in high risk HIV patients.

Rev Esp Quimioter 2021;34(5):459-467 [Full-text PDF]